Quanterix Fifth–generation Psa Test Enables More Sensitive Measurements Following
Clinical Chemistry Publication Highlights Analytical Performance
Cambridge, MA – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced that the analytical performance of its Prostate Specific Antigen (PSA) test, a fifth–generation digital immunoassay, demonstrated a 2–log improvement in sensitivity over today’s ultrasensitive third–generation PSA assays used to measure PSA levels in patients following radical prostatectomy. The results were published online by Clinical Chemistry.
“Quanterix has developed and validated a test that enables reliable measurements of PSA in men who have undergone radical prostatectomy for prostate cancer. Following surgery, PSA levels typically drop to ‘undetectable’ with conventional third–generation tests, but we were able to accurately measure PSA with high precision in all samples evaluated,” stated David Wilson Ph.D., Senior Director, Product Development at Quanterix and lead author of the study. The analytical performance of this assay is further highlighted in the publication, and complements clinical data that has recently been published which suggests this test is a reliable predictor of five–year biochemical recurrence–free survival following surgery. Dr. Wilson continued, “Increasing evidence suggests that a more sensitive PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically.”
“Quanterix is developing a menu of high quality thoroughly characterized assays that will demonstrate the value of our SiMoA platform in both the life sciences and in vitro diagnostics markets. These results provide another great example of how transformative sensitivity will allow us to deliver on the promise of next generation digital molecular diagnostics,” said Martin Madaus, Ph.D., Chairman and CEO of Quanterix.
Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000–fold improvement in sensitivity compared with today’s analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness. Founded in 2007, the privately held Cambridge, Massachusetts–based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.
Share this page